interleukin-7 receptor modulators (OSE Immunotherapeutics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameinterleukin-7 receptor modulators (OSE Immunotherapeutics)
Drug Alias NameEFFIMAB project (Effimune)interleukin-7 receptor modulators (Effimune)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInterleukin-7 receptors antagonists
TargetsInterleukin-7 receptors
Therapy Area/IndicationsColitis, UlcerativePrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEffimune
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOSE Immunotherapeutics SAEffimune
Active IndicationsN/A
Inactive IndicationsColitis, UlcerativePrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A